Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 693 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 693 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $32.19, for a total transaction of $22,307.67. Following the sale, the insider directly owned 175,868 shares of the company’s stock, valued at $5,661,190.92. This represents a 0.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Jason Adair also recently made the following trade(s):

• On Tuesday, November 18th, Jason Adair sold 35,656 shares of Liquidia stock. The stock was sold at an average price of $30.03, for a total transaction of $1,070,749.68.
• On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The stock was sold at an average price of $22.93, for a total transaction of $15,867.56.
• On Monday, October 13th, Jason Adair sold 3,670 shares of Liquidia stock. The stock was sold at an average price of $23.41, for a total transaction of $85,914.70.

Liquidia Trading Down 3.9%

LQDA stock traded down $1.26 during midday trading on Tuesday, hitting $30.79. The stock had a trading volume of 1,614,836 shares, compared to its average volume of 2,006,737. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The firm has a market cap of $2.68 billion, a P/E ratio of -21.38 and a beta of 0.48. The business has a fifty day moving average price of $25.41 and a two-hundred day moving average price of $21.48. Liquidia Corporation has a 1-year low of $10.37 and a 1-year high of $32.80.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.41. The firm had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm’s revenue for the quarter was up 1106.7% on a year-over-year basis. On average, sell-side analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

LQDA has been the topic of several recent analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price target on shares of Liquidia in a research note on Monday, November 3rd. Needham & Company LLC lifted their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. HC Wainwright increased their target price on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Wells Fargo & Company initiated coverage on shares of Liquidia in a report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price target for the company. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $38.56.

Institutional Trading of Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Farallon Capital Management LLC raised its holdings in Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Liquidia by 10.2% during the third quarter. Vanguard Group Inc. now owns 3,961,217 shares of the company’s stock worth $90,078,000 after acquiring an additional 367,659 shares in the last quarter. Opaleye Management Inc. raised its holdings in shares of Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after acquiring an additional 215,000 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Liquidia in the 3rd quarter worth about $38,887,000. Finally, Caprock Group LLC bought a new position in Liquidia in the 3rd quarter valued at about $37,114,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).